Rosa Parisi

Rosa Parisi

Auto-generated profile, based on publicly available information

Rosa Parisi

Division of Informatics, Imaging and Data Sciences, School of Health Sciences, Faculty of Biology, Medicine and Health University of Manchester Manchester UK

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2013 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
RPRosa Parisi
Rosa Parisi
DSDeborah P.M. Symmons
Deborah P.M. Symmons
Chris EM GriffithsChris EM Griffiths
Chris EM Griffiths
DADarren M. Ashcroft
Darren M. Ashcroft

28 May 2020 in BMJ
Verified
Journal Article
Open access
PDF file
RPRosa Parisi
Rosa Parisi
IIIreny Y K Iskandar
Ireny Y K Iskandar
EKEvangelos HEATHER Kontopantelis
Evangelos HEATHER Kontopantelis
MAMatthias Augustin
Matthias Augustin
CGChristopher E M Griffiths
Christopher E M Griffiths
DADarren M Ashcroft
Darren M Ashcroft
Objective To systematically review and provide information on the incidence of psoriasis and quantify global, regional, and country specific estimates of its prevalence. Design Systematic review and meta-analysis. Data sources Medline, Embase, Web of Science, SciELO, Korean Journal Databases, Russian Science Citation Index, WPRIM, SaudiMedLit, Informit, IndMed, and HERDIN were searched systematically from their inception dates to October 2019. Methods Studies were included if they reported on the incidence or prevalence of psoriasis in the general population. Incidence data were summarised descriptively, whereas bayesian hierarchical models were fitted to estimate the global, regional, and country specific prevalence of psoriasis. Results 41 164 records were identified and 168 studies met the inclusion criteria. In adults, the incidence of psoriasis varied from 30.3 per 100 000 person years (95% confidence interval 26.6 to 34.1) in Taiwan to 321.0 per 100 000 person years in Italy. The prevalence of psoriasis varied from 0.14% (95% uncertainty interval 0.05% to 0.40%) in east Asia to 1.99% (0.64% to 6.60%) in Australasia. The prevalence of psoriasis was also high in western Europe (1.92%, 1.07% to 3.46%), central Europe (1.83%, 0.62% to 5.32%), North America (1.50%, 0.63% to 3.60%), and high income southern Latin America (1.10%, 0.36% to 2.96%). Conclusions Eighty one per cent of the countries of the world lack information on the epidemiology of psoriasis. The disease occurs more frequently in adults than in children. Psoriasis is unequally distributed across geographical regions; it is more frequent in high income countries and in regions with older populations. The estimates provided can help guide countries and the international community when making public health decisions on the appropriate management of psoriasis and assessing its natural history over time. Systematic review registration PROSPERO CRD42019160817.

22 December 2016 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
DSD.A. Springate
D.A. Springate
RPR. Parisi
R. Parisi
EKEvangelos HEATHER Kontopantelis
Evangelos HEATHER Kontopantelis
DRD. Reeves
D. Reeves
Chris EM GriffithsChris EM Griffiths
Chris EM Griffiths
DAD.M. Ashcroft
D.M. Ashcroft
The burden of psoriasis across many world regions is high and there is a recognised need to better understand the epidemiology of this common skin disorder. To examine changes in the prevalence and incidence of psoriasis, and mortality rates over a 15 year period. Cohort study involving analysis of longitudinal electronic health records between 1999 and 2013 using the UK Clinical Practice Research Datalink (CPRD). The prevalence of psoriasis increased steadily from 2.3% (2297 cases per 100,000) in 1999 to 2.8% (2815 per 100,000) in 2013, which does not appear to be attributable to changes in incidence rates. We observed peaks in age-bands characteristic of early (type I) and late-onset (type II) psoriasis, and changes in incidence and prevalence rates with increasing latitude in the UK. All-cause mortality rates for the general population and for patients with psoriasis have decreased over the last 15 years. However, the risk of all-cause mortality for psoriasis patients remains elevated compared to people without psoriasis (hazard ratio (HR) 1.21; 95% CI 1.13-1.3) and we found no significant change in this relative excess mortality gap over time. We found an increasing population living longer with psoriasis in the UK which has important implications for healthcare service delivery and for resource allocation. Importantly, early mortality in patients with psoriasis remains elevated compared to the general population and we found no evidence of change in this premature mortality gap.

18 June 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DSDavid A. Springate
David A. Springate
EKEvangelos HEATHER Kontopantelis
Evangelos HEATHER Kontopantelis
DADarren M. Ashcroft
Darren M. Ashcroft
IOIvan Olier
Ivan Olier
RPRosa Parisi
Rosa Parisi
DRDavid Reeves
David Reeves
Lists of clinical codes are the foundation for research undertaken using electronic medical records (EMRs). If clinical code lists are not available, reviewers are unable to determine the validity of research, full study replication is impossible, researchers are unable to make effective comparisons between studies, and the construction of new code lists is subject to much duplication of effort. Despite this, the publication of clinical codes is rarely if ever a requirement for obtaining grants, validating protocols, or publishing research. In a representative sample of 450 EMR primary research articles indexed on PubMed, we found that only 19 (5.1%) were accompanied by a full set of published clinical codes and 32 (8.6%) stated that code lists were available on request. To help address these problems, we have built an online repository where researchers using EMRs can upload and download lists of clinical codes. The repository will enable clinical researchers to better validate EMR studies, build on previous code lists and compare disease definitions across studies. It will also assist health informaticians in replicating database studies, tracking changes in disease definitions or clinical coding practice through time and sharing clinical code information across platforms and data sources as research objects.

1 May 2020 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
III.Y.K. Iskandar
I.Y.K. Iskandar
RPR. Parisi
R. Parisi
CGC.E.M. Griffiths
C.E.M. Griffiths
DAD.M. Ashcroft
D.M. Ashcroft
TAthe Global Psoriasis Atlas
the Global Psoriasis Atlas
Background There is a lack of any overview of changes over time and variation in the epidemiology of psoriasis with age and between genders. Objectives To perform a systematic review of published population‐based studies on variations in psoriasis incidence and prevalence with age and between genders, and to explore trends in psoriasis epidemiology over time. Methods Eleven electronic and regional databases were searched from their inception dates to October 2019. No language restrictions were applied. Studies where eligible if they reported on changes in psoriasis incidence and/or prevalence over time and/or by age group and gender. Results A total of 308 papers were critically appraised, of which 90 studies from 22 countries were included. Incidence data confirmed a clear bimodal age pattern in psoriasis onset, with the first and second peak at around 30‐39 and 60‐69 years of age, respectively, with evidence suggesting it presents slightly earlier in women than men. Whilst prevalence data showed an increasing trend with age until around 60 or 70 years, after which it decreases. Although there was lack of agreement on specific gender differences in psoriasis incidence and prevalence, a slight male predominance was reported in several studies. Studies worldwide suggested a stable or a slightly decreasing trend in psoriasis incidence, whilst an increasing trend in psoriasis prevalence has been consistently reported. One particular challenge faced was the vastly different methodologies used in the included studies, which contributed to some of the heterogeneity of the results. Conclusions Studies on changes over time in the occurrence of psoriasis have contributed to a greater appreciation of the increasing burden of the disease. However, further research is required to determine the reason driving the increase in psoriasis prevalence over time.

1 September 2015 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
PDF file
RPRosa Parisi
Rosa Parisi
MRMartin K. Rutter
Martin K. Rutter
MLMark Lunt
Mark Lunt
HYHelen S. Young
Helen S. Young
DSDeborah P.M. Symmons
Deborah P.M. Symmons
DADarren M. Ashcroft
Darren M. Ashcroft
The association between psoriasis and risk of major cardiovascular (CV) events (myocardial infarction, acute coronary syndrome, unstable angina, and stroke) is unclear. A cohort study with 48,523 patients with psoriasis and 208,187 controls was conducted. During a median follow-up of 5.2 years, 1,257 patients with psoriasis (2.59%) had a major CV event, compared with 4,784 controls (2.30%). In the multivariable analysis, inflammatory arthritis hazard ratio (HR) 1.36 (1.18–1.58), diabetes HR 1.18 (1.06–1.31), chronic kidney disease HR 1.18 (1.07–1.31), hypertension HR 1.37 (1.29–1.45), transient ischemic attack HR 2.74 (2.41–3.12), atrial fibrillation HR 1.54 (1.36–1.73), valvular heart disease HR 1.23 (1.05–1.44), thromboembolism 1.32 (1.17–1.49), congestive heart failure HR 1.57 (1.39–1.78), depression HR 1.16 (1.01–1.34), current smoker HR 2.18 (2.03–2.33), age (year) HR 1.07 (1.07–1.07), and male gender HR 1.83 (1.69–1.98) were statistically significant for the risk of major CV events. The age- and gender-adjusted HRs of a major CV event for psoriasis were 1.10 (1.04–1.17) and for severe psoriasis 1.40 (1.07–1.84), whereas the fully adjusted HRs were attenuated to 1.02 (0.95–1.08) and 1.28 (0.96–1.69). In conclusion, neither psoriasis nor severe psoriasis were associated with the short-to-medium term (over 3–5 years) risk of major CV events after adjusting for known cardiovascular disease risk factors.